$4.74M Direct Offering Priced at $1.60, a Discount to the $1.66 Close
BIVI has more than doubled off its 52-week low of $0.82 on elevated volume (2.8× avg).
Summary
BioVie sold 2,962,500 shares to a single healthcare-focused institutional investor at $1.60, roughly 4% below the $1.66 market price, for about $4.74 million gross. The same investor also gets 2,962,500 warrants at a $1.70 strike, exercisable in six months and expiring in five and a half years, which adds meaningful future dilution on top of the shares. The raise is small relative to a company that posted a $22.1M loss and carried a going concern warning in its August 10-K, and it comes the same day BioVie cut its A.G.P. ATM program from $6.46 million to $1.225 million after selling only about $283,000. That combination says the ATM channel was not raising money, so the company went to a single institutional buyer instead. Closing is expected on or about November 5, 2026.
At the time of this announcement, BIVI was trading at $1.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.8M. The 52-week trading range was $0.82 to $3.79. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.